NCR3 and neoplasm: In contrast, treatment with NKp30-Ig (n = 10) resulted in a remarkable suppression of tumor development; as from the second administration of NKp30-Ig (at day 7), tumors size remained constant for three weeks and only a moderate progression was detected in the following days (figure 2).